Fulcrum Therapeutics, Inc. expected to post a loss of 14 cents a share - Earnings Preview

Fulcrum Therapeutics

23/10/2026 13:59

Fulcrum Therapeutics, Inc. FULC.OQ FULC.O is expected to  show no change in quarterly revenue when it reports  results on October 27 (estimated) for the period ending September 30 2026

​LSEG's mean analyst estimate for Fulcrum Therapeutics, Inc. is for a loss of 14 cents per share. 
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Fulcrum Therapeutics, Inc. is $4.00, about 8.7% above its last closing price of $3.68
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.17
-0.22
-0.22
Met
0
Mar. 31 2026
-0.30
-0.30
-0.25
Beat
16.2
Dec. 31 2025
-0.31
-0.31
-0.31
Met
-0.3​
Sep. 30 2025
-0.29
-0.29
-0.31
Missed
-5.5
​​Jun. 30 2025
-0.29
-0.29
-0.28
Beat
3.4
Mar. 31 2025
-0.30
-0.29
-0.28
Beat
4.8​
Dec. 31 2024
-0.29
-0.32
-0.31
Beat
3.6
Sep. 30 2024
-0.41
-0.41
-0.35
Beat
13.7
This summary was machine generated October 23 at 12:59 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)